378 related articles for article (PubMed ID: 33837006)
1. Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.
Wang L; Sfakianos JP; Beaumont KG; Akturk G; Horowitz A; Sebra RP; Farkas AM; Gnjatic S; Hake A; Izadmehr S; Wiklund P; Oh WK; Szabo PM; Wind-Rotolo M; Unsal-Kacmaz K; Yao X; Schadt E; Sharma P; Bhardwaj N; Zhu J; Galsky MD
Clin Cancer Res; 2021 Aug; 27(15):4287-4300. PubMed ID: 33837006
[TBL] [Abstract][Full Text] [Related]
2. Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.
Kates M; Nirschl TR; Baras AS; Sopko NA; Hahn NM; Su X; Zhang J; Kochel CM; Choi W; McConkey DJ; Drake CG; Bivalacqua TJ
Eur Urol Oncol; 2021 Feb; 4(1):117-120. PubMed ID: 31411999
[TBL] [Abstract][Full Text] [Related]
3. Molecular determinants of response to PD-L1 blockade across tumor types.
Banchereau R; Leng N; Zill O; Sokol E; Liu G; Pavlick D; Maund S; Liu LF; Kadel E; Baldwin N; Jhunjhunwala S; Nickles D; Assaf ZJ; Bower D; Patil N; McCleland M; Shames D; Molinero L; Huseni M; Sanjabi S; Cummings C; Mellman I; Mariathasan S; Hegde P; Powles T
Nat Commun; 2021 Jun; 12(1):3969. PubMed ID: 34172722
[TBL] [Abstract][Full Text] [Related]
4. NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
Yan S; Zeng H; Jin K; Shao F; Liu Z; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Xu J
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35523436
[TBL] [Abstract][Full Text] [Related]
5. Single-cell atlases link macrophages and CD8
Liang Y; Tan Y; Guan B; Guo B; Xia M; Li J; Shi Y; Yu Z; Zhang Q; Liu D; Yang X; Hao J; Gong Y; Shakeel M; Zhou L; Ci W; Li X
Theranostics; 2022; 12(18):7745-7759. PubMed ID: 36451860
[No Abstract] [Full Text] [Related]
6. Gender-specific Stratification of Survival Following Immune Checkpoint Inhibitor Therapy Based on Intratumoral Expression of a B cell Gene Signature.
Aragaki AK; Jing Y; Hoffman-Censits J; Choi W; Hahn NM; Trock BJ; McConkey DJ; Johnson BA
Eur Urol Oncol; 2022 Jun; 5(3):338-346. PubMed ID: 34426176
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
Rose TL; Weir WH; Mayhew GM; Shibata Y; Eulitt P; Uronis JM; Zhou M; Nielsen M; Smith AB; Woods M; Hayward MC; Salazar AH; Milowsky MI; Wobker SE; McGinty K; Millburn MV; Eisner JR; Kim WY
Br J Cancer; 2021 Oct; 125(9):1251-1260. PubMed ID: 34294892
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors.
Plage H; Furlano K; Hofbauer S; Weinberger S; Ralla B; Franz A; Fendler A; de Martino M; Roßner F; Elezkurtaj S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Zecha H; Minner S; Simon R; Sauter G; Weischenfeldt J; Klatte T; Schlomm T; Horst D; Schallenberg S
BMC Urol; 2024 Apr; 24(1):96. PubMed ID: 38658905
[TBL] [Abstract][Full Text] [Related]
9. TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
Jin K; Xu J; Su X; Xu Z; Li B; Liu G; Liu H; Wang Y; Zhu Y; Xu L; Zhang W; Liu Z; Wang Z; Chang Y; Xu J
J Pathol; 2024 Jun; 263(2):139-149. PubMed ID: 38380548
[TBL] [Abstract][Full Text] [Related]
10. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
11. Myeloid Resistance is not Futile: Biomarkers of Immunotherapy in Bladder Cancer.
Drake CG
Clin Cancer Res; 2021 Aug; 27(15):4139-4141. PubMed ID: 34045294
[TBL] [Abstract][Full Text] [Related]
12. Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
Powles T; Necchi A; Rosen G; Hariharan S; Apolo AB
Clin Genitourin Cancer; 2018 Apr; 16(2):117-129. PubMed ID: 29325739
[TBL] [Abstract][Full Text] [Related]
13. Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition.
Erlmeier F; Klümper N; Landgraf L; Strissel PL; Strick R; Sikic D; Taubert H; Wach S; Geppert CI; Bahlinger V; Breyer J; Ritter M; Bolenz C; Roghmann F; Erben P; Schwamborn K; Wirtz RM; Horn T; Wullich B; Hölzel M; Hartmann A; Gschwend JE; Weichert W; Eckstein M
Eur Urol; 2023 Feb; 83(2):133-142. PubMed ID: 36372626
[TBL] [Abstract][Full Text] [Related]
14. Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
Niglio SA; Jia R; Ji J; Ruder S; Patel VG; Martini A; Sfakianos JP; Marqueen KE; Waingankar N; Mehrazin R; Wiklund P; Oh WK; Mazumdar M; Ferket BS; Galsky MD
Eur Urol; 2019 Dec; 76(6):782-789. PubMed ID: 31200951
[TBL] [Abstract][Full Text] [Related]
15.
Klümper N; Wüst L; Saal J; Ralser DJ; Zarbl R; Jarczyk J; Breyer J; Sikic D; Wullich B; Bolenz C; Roghmann F; Hölzel M; Ritter M; Strieth S; Hartmann A; Erben P; Wirtz RM; Landsberg J; Dietrich D; Eckstein M
Oncoimmunology; 2023; 12(1):2267744. PubMed ID: 37868689
[TBL] [Abstract][Full Text] [Related]
16. Focus on Biochemical and Clinical Predictors of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma: Where Do We Stand?
Roviello G; Catalano M; Nobili S; Santi R; Mini E; Nesi G
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114616
[TBL] [Abstract][Full Text] [Related]
17. Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.
Joshi M; Grivas P; Mortazavi A; Monk P; Clinton SK; Sue-Ann Woo M; Holder SL; Drabick JJ; Yin M
Cancer Med; 2020 Dec; 9(24):9365-9372. PubMed ID: 33098265
[TBL] [Abstract][Full Text] [Related]
18. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient.
Lee HW; Chung W; Lee HO; Jeong DE; Jo A; Lim JE; Hong JH; Nam DH; Jeong BC; Park SH; Joo KM; Park WY
Genome Med; 2020 May; 12(1):47. PubMed ID: 32460812
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.
Miller EJ; Rose TL; Maughan BL; Milowsky MI; Bilen MA; Carthon BC; Gao X; Rapisuwon S; Zhao Q; Yu M; Agarwal N; Galsky MD
Cancer; 2024 May; 130(9):1642-1649. PubMed ID: 38180804
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological characteristics, molecular landscape, and biomarker landscape for predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese population with mismatch repair deficient urothelial carcinoma: a real-world study.
Ma YT; Hua F; Zhong XM; Xue YJ; Li J; Nie YC; Zhang XD; Ma JW; Lin CH; Zhang HZ; He W; Sha D; Zhao MQ; Yao ZG
Front Immunol; 2023; 14():1269097. PubMed ID: 38022513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
